Postoperative therapy patterns for thymic carcinoma with complete resection: retrospective analysis of 120 patients
Strahlentherapie und Onkologie · 2025
DOI: 10.1007/s00066-025-02410-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Strahlentherapie und Onkologie, 2025. Verfasst von Yan Gao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shanghai Cancer Center, Fudan University, 270 Dong'an Road, 200032, Shanghai, China. Hauptthemen laut MEDLINE: Thymus Neoplasms, Thymoma, Postoperative Care, Thymectomy. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Special Project for Research and Development in Key areas of Guangdong Province.
Abstract (Originalsprache)
INTRODUCTION: This study aimed to determine the role of postoperative adjuvant therapy in patients with thymic carcinoma following complete resection. METHODS: We conducted a retrospective analysis of patients with stage I-III or N1+ thymic carcinomas who underwent complete resection at our center between 2006 and 2020. Data on the clinical characteristics and postoperative adjuvant therapies were collected. RESULTS: One hundred and twenty patients were enrolled. Five (4.2%) patients received only postoperative chemotherapy, 36 (33.0%) received only postoperative radiotherapy, 75 (62.5%) received postoperative chemoradiotherapy, and four (3.3%) did not receive any postoperative therapy. During a median follow-up period of 65 months, disease failure was observed in 46 (38.3%) patients, and 28 (23.3%) patients died. The 5‑year disease-free survival (DFS) and overall survival (OS) rates were 58.7 and 81.4%, respectively. Patients who underwent different postoperative therapies exhibited varying prognoses. Radiotherapy reduced the risks of failure (p < 0.001) and death (p < 0.001), whereas chemotherapy did not (p = 0.198 and 0.260 respectively). Subgroup analyses revealed that stage III/IV patients who received chemotherapy had a lower relapse risk (p = 0.045) and improved OS (p = 0.064). Multivariate analysis demonstrated that radiotherapy alone (hazard ratio [HR], 0.24; p = 0.023) independently predicted OS. CONCLUSIONS: Adjuvant radiotherapy should be recommended for patients with thymic carcinoma who have undergone complete resection. Further exploration is needed to clarify the role of adjuvant chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Shanghai Cancer Center, Fudan University, 270 Dong'an Road, 200032, Shanghai, China.
- Department of Oncology, The People's Hospital of Cangnan, Cangnan, Zhejiang Province, China.
- Department of Radiation Oncology, Shanghai Cancer Center, Fudan University, 270 Dong'an Road, 200032, Shanghai, China. wenxingfan@126.com.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. wenxingfan@126.com.
- Shanghai Key Laboratory of Radiation Oncology, Shanghai, China. wenxingfan@126.com.
- Shanghai Clinical Research Center for Radiation Oncology, Shanghai, China. wenxingfan@126.com.
Förderung
- Special Project for Research and Development in Key areas of Guangdong Province
Zitieren
APA
Gao, Y., Fan, X., Zheng, H., Cui, Y., Yi, Q., Li, Y., Pei, Y., & Wu, K. (2025). Postoperative therapy patterns for thymic carcinoma with complete resection: retrospective analysis of 120 patients. Strahlentherapie und Onkologie. https://doi.org/10.1007/s00066-025-02410-2
Vancouver
Gao Y, Fan X, Zheng H, Cui Y, Yi Q, Li Y, et al. Postoperative therapy patterns for thymic carcinoma with complete resection: retrospective analysis of 120 patients. Strahlentherapie und Onkologie. 2025. doi:10.1007/s00066-025-02410-2
BibTeX
@article{Gao2025,
author = {Gao, Yan and Fan, Xingwen and Zheng, Hong and Cui, Yingshan and Yi, Qiong and Li, Yaqi and Pei, Yulei and Wu, Kailiang},
title = {Postoperative therapy patterns for thymic carcinoma with complete resection: retrospective analysis of 120 patients},
journal = {Strahlentherapie und Onkologie},
year = {2025},
doi = {10.1007/s00066-025-02410-2}
}
EUVIMED